ST2在急性心力衰竭中的预后价值

doi:10.3969/j.issn.1002-1949.2018.01.010

摘要
图/表
参考文献(32)
相关文章 (15)

全文: PDF (518 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 ST2与IL-33结合能够减少心肌纤维化，抑制心肌肥大，减少心肌凋亡及改善心脏功能。sST2可以欺骗性地与IL-33结合抑制心肌保护作用。截止目前，发现ST2在社区人群中的参考值范围与性别有关，与年龄关系不确切；ST2对于急性心力衰竭（AHF）的诊断价值不大，却能较好地独立预测AHF患者不良心血管事件的发生，尤其是死亡和心力衰竭再住院;连续监测ST2浓度可能预测价值更大，而且有可能在指导治疗方面发挥重要作用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	孟冲
	商德亚
	王娟

收稿日期: 2017-08-28

通讯作者: 商德亚（1964-），男，博士，主任医师，硕士生导师，急救中心主任，E-mail:Sdsllysdy123@163.com。

作者简介: 孟冲（1982-），男，博士，主治医师，E-mail：mengchong224@163.com。

引用本文:

孟冲，商德亚，王娟. ST2在急性心力衰竭中的预后价值[J]. 中国急救医学, 2018, 38(1): 41-45.
Meng Chong,Shang De-ya, Wang Juan. ST2 and prognosis in acute heart failure. Chinese Journal of Critical Care Medicine, 2018, 38(1): 41-45.

链接本文:

http://www.cnemergency.org.cn/CN/10.3969/j.issn.1002-1949.2018.01.010 或 http://www.cnemergency.org.cn/CN/Y2018/V38/I1/41

［1］Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-〖JP〗like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines［J］. Immunity, 2005, 23(5): 479-490. ［2］Weinberg EO, Shimpo M, Keulenaer GW, et al. Expression and regulation of ST2,an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction［J］. Circulation, 2002, 106(23): 2961-2966. ［3］Baba Y, Maeda K, Yashiro T, et al. GATA2 is a critical transactivator for the human IL1RL1/ST2 promoter in mast cells/basophils: opposing roles for GATA2 and GATA1 in human IL1RL1/ST2 gene expression ［J］. J Biol Chem, 2012, 287(39):32 689-32 696. ［4］Shimizu M, Matsuda A, Yanagisawa K, et al. Functional SNPs in the distal promoter of the ST2 gene are associated with atopic dermatitis［J］. Hum Mol Genet, 2005, 14(15): 2919-2927. ［5］Ho JE, Chen W-Y, Chen M-H, et al. Common genetic variation at the IL1RL1 locus regulates IL-33/ST2 signaling［J］. J Clin Invest, 2013,123(10):4208-4218. ［6］Lu J, Snider JV, Grenache DG. Establishment of reference intervals for soluble ST2 from a United States population［J］. Clin Chim Acta, 2010,411(21-22):1825-1826. ［7］Coglianese EE, LarsonMG, Vasan RS, et al. Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study［J］. Clin Chem, 2012,58:1673-1681. ［8］王运红,周琼,安涛,等.中国社区人群可溶性ST2血浆水平的参考值范围及影响因素［J］.中国心血管病杂志，2015，43(10):900-903. ［9］Wu AH, Wians F, Jaffe A. Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implication on interpretation of test results［J］. Am Heart J, 2013, 165(6):995-999. ［10］Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker［J］. Nat Rev Drug Discov, 2008,7(10):827-840. ［11］Sánchez-Más J, Lax A, Asensio-López Mdel C, et al. Modulation of IL-33/ST2 system in post-infarction heart failure: correlation with cardiac remodeling markers［J］. Eur J Clin Invest, 2014, 44(7):643-651.  ［12］Sanada S, Hakuno D, Higgins LJ,et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system［J］. J Clin Invest,2007,117(6):1538-1549. ［13］Weir RA, Miller AM, Murphy GE,et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction［J］. J Am Coll Cardiol, 2010, 55(3):243-250. ［14］Shah RV, Chen-Tournoux AA, Picard MH, et al. Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea［J］. Circ Heart Fail, 2009,2(4):311-319.  ［15］Januzzi JL Jr, Peacock WF, Maisel AS, et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study［J］. J Am Coll Cardiol, 2007, 50(7): 607-613. ［16］Seki K, Sanada S, Kudinova AY, et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling［J］. Circ Heart Fail, 2009, 2(6): 684-691. ［17］Yndestad A, Marshall AK, Hodgkinson JD, et al. Modulation of interleukin signalling and gene expression in cardiac myocytes by endothelin-1［J］. Int J Biochem Cell Biol, 2010,42(2):263-272. ［18］许亚妹, 葛均波. 新型心衰标志物sST2 的生物学特征和临床意义［J］. 中华检验医学杂志, 2015, 38(7): 498-501. ［19］Mueller T, Dieplinger B, Gegenhuber A, et al. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure［J］. Clin Chem, 2008, 54(4):752-756. ［20］Rehman SU, Mueller T, Januzzi Jr JL. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure［J］. J Am Coll Cardiol, 2008, 52(18):1458-1465. ［21］Manzano-Fernández S, Mueller T, Pascual-Figal D, et al. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction［J］. Am J Cardiol, 2011,107(2):259-267. ［22］Pascual-Figal DA, Manzano-Fernández S, Boronat M, et al. Soluble ST2, high sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure［J］. Eur J Heart Fail, 2011, 13(7):718-725. ［23］Ahmad T, Fiuzat M, Neely B, et al. Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure［J］. JACC Heart Fail, 2014, 2(3): 260-268. ［24］Fries F, Loureno P, Laszczynska O, et al. Prognostic value of sST2 added to BNP in acute heart failure with preserved or reduced ejection fraction［J］. Clin Res Cardiol,2015,104(6):491-499.  ［25］Kim MS, Jeong TD, Han SB, et al. Role of Soluble ST2 as a Prognostic Marker in Patients with Acute Heart Failure and Renal Insufficiency［J］. J Korean Med Sci, 2015,30(5):569-575.  ［26］Boisot S, Beede J, Isakson S, et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure［J］. J Card Fail, 2008, 14(9):732-738. ［27］Manzano-Fernández S, Januzzi JL, Pastor-Pérez FJ, et al. Serialmonitoring of soluble interleukin family member ST2 in patients with acutely decompensated heart failure［J］. Cardiology, 2012,122(3):158-166. ［28］Breidthardt T, Balmelli C, Twerenbold R, et al. Heart failure therapy-induced early ST2 changes may offer long-term therapy guidance［J］. J Card Fail, 2013,19(12):821-828. ［29］Llibre C, Zamora E, Caballero , et al. The real-life value of ST2 monitoring during heart failure decompensation: impact on long-term readmission and mortality［J］. Biomarkers,2016,21(3):225-232.  ［30］Januzzi JL, Mebazaa A, Di Somma S. ST2 and Prognosis in Acutely Decompensated Heart Failure: The International ST2 Consensus Panel［J］. Am J Cardiol, 2015, 115 (7 Suppl):26B-31B. ［31］Skvortsov AA,Protasov VN, Narusov OY, et al. Soluble Suppression〖JP〗 of Tumorogenicity 2 Increases Opportunities for Risk Stratification After Acute Heart Failure Decompensation［J］. Kardiologiia, 2017,1:48-58. ［32］Tang WH, Wu Y, Grodin JL, et al. Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure［J］. JACC Heart Fail, 2016,4(1):68-77.